NUVG yields 5000.00% · ABBV yields 3.09%● Live data
📍 NUVG pulled ahead of the other in Year 1
Combined, NUVG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NUVG + ABBV for your $10,000?
HempTech Corporation, a technology company, provides Controlled Environment Agriculture (CEA) solutions with automation and analytical tools for the cultivators of legal industrial hemp and cannabis in the United States. The company's products and solutions include Grow.droid, a self-contained fully-automated platform for growing cannabis; CognetiX, a suite of software solutions that integrates plant and business data into a real-time, distributed grow control platform; Mithra intelligent lighting that is an LED lighting technology for indoor growing facilities; and GROWComm solutions, which is a community comprising engineers, legacy growers, entrepreneurs, market researchers, and industry pioneers to address the needs of the agriculture and cannabis grow industry. Its solutions also include SmartNergy, an energy management and control product for the indoor agriculture industry; SmartSense, a sensor and control product for the agriculture industry that provides sensors and sensor networks for indoor growing facilities; and SPIDer (secure perimeter intrusion detection network) solution that addresses the potential threat facing the cannabis/hemp industry. The company is based in Saint Petersburg, Florida. HempTech Corporation operates as a subsidiary of FutureWorld Corp.
Full NUVG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.